摘要
支气管哮喘是儿童呼吸道常见的慢性炎症,而特异性免疫治疗(SIT)作为唯一能改变其自然进程的治疗方法,不仅可以减少临床症状,还可以预防新变应原的产生。现舌下特异性免疫治疗因其良好的安全性及有效性,而且操作简单,也逐渐在我国广泛开展。随着对其作用机制的不断深入研究,以及新变应原制剂逐步优化,SIT的应用范围将会进一步扩大。而本文主要是针对儿童哮喘的特异性免疫治疗方案的最近研究进展予以综述,明确其治疗机制、适用范围及疗效评价等,以便规范临床治疗方案的选择,使儿童哮喘达到更好的治疗效果。
Bronchoal asthma is a common chronic inflammation in children's respiratory tract, and specific immunotherapy(SIT), as the only treatment method that can change its natural progression, not only can reduce clinical symptoms, but also prevent the production of new allergens. Sublingual specific immunotherapy is widely used in China because of its good safety and effectiveness, as well as its simple operation. With the continuous in-depth research on its mechanism of action and the gradual optimization of new allergen preparations, the scope of application of SIT will be further expanded. This article is mainly to review the recent research progress of specific immunotherapy programs for children with asthma, to clarify its treatment mechanism, scope of application and evaluation of efficacy, etc., so as to standardize the selection of clinical treatment options, so that better therapeutic results for children's asthma can be achieved.
作者
姚珂
章爱莲
YAO Ke;ZHANG Ailian(Faculty of Pediatric Sciences,Bengbu Medical College,Bengbu 233000,China;Department of Pediatrics, Jiaxing Second Hospital in Zhejiang Province,Jiaxing 314000,China)
出处
《中国现代医生》
2018年第34期165-168,共4页
China Modern Doctor
基金
浙江省嘉兴市第二批科技计划项目(2013AY21059)
